Unicycive Therapeutics (UNCY) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.36, -6.41% vs the prior close of $3.59.
- Volume 1.08M shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
UNCY slides 6.4% to $3.36, a 52-week low, 5 down days in a row. Closed at $3.36, -6.41% vs the prior close of $3.59. Day range $3.35–$3.58, opened at $3.58.
UNCY daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — UNCY slides 6.4% to $3.36, a 52-week low, 5 down days in a row
- Closed at $3.36, -6.41% vs the prior close of $3.59. Day range $3.35–$3.58, opened at $3.58.
- Volume was 1.08M shares, 1.3x its 50-day average of 854.84K.
- Price is -30.9% vs its 50-day average ($4.86) and -45.9% vs its 200-day average ($6.21).
- 52-week range $3.35–$8.74; today's close sits at 0% of that range, 61.6% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — UNCY dips 3.0% to $3.59, a 52-week low, 4 down days in a row
- Closed at $3.59, -2.97% vs the prior close of $3.70. Day range $3.56–$3.71, opened at $3.70.
- Volume was 893.00K shares, 1.0x its 50-day average of 852.28K.
- Price is -26.6% vs its 50-day average ($4.89) and -42.3% vs its 200-day average ($6.22).
- 52-week range $3.56–$8.74; today's close sits at 1% of that range, 58.9% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — UNCY dips 0.8% to $3.70, a 52-week low, 3 down days in a row
- Closed at $3.70, -0.80% vs the prior close of $3.73. Day range $3.59–$3.81, opened at $3.73.
- Volume was 1.21M shares, 1.4x its 50-day average of 845.27K.
- Price is -24.9% vs its 50-day average ($4.93) and -40.7% vs its 200-day average ($6.24).
- 52-week range $3.59–$8.74; today's close sits at 2% of that range, 57.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — UNCY slides 7.9% to $3.73, a 52-week low on 2.2x normal volume
- Closed at $3.73, -7.90% vs the prior close of $4.05. Day range $3.67–$4.02, opened at $3.99.
- Volume was 1.84M shares, 2.2x its 50-day average of 820.30K — unusually heavy trading.
- Price is -24.7% vs its 50-day average ($4.96) and -40.3% vs its 200-day average ($6.25).
- 52-week range $3.67–$8.74; today's close sits at 1% of that range, 57.3% below the 52-week high.
Oct 12, 2026 — UNCY dips 1.5% to $4.05, a 52-week low
- Closed at $4.05, -1.46% vs the prior close of $4.11. Day range $3.99–$4.11, opened at $4.10.
- Volume was 912.80K shares, 1.1x its 50-day average of 811.76K.
- Price is -18.7% vs its 50-day average ($4.98) and -35.3% vs its 200-day average ($6.26).
- 52-week range $3.93–$8.74; today's close sits at 2% of that range, 53.7% below the 52-week high.
Oct 9, 2026 — UNCY rises 1.0% to $4.11
- Closed at $4.11, +0.98% vs the prior close of $4.07. Day range $4.05–$4.20, opened at $4.07.
- Volume was 551.40K shares, 0.7x its 50-day average of 817.40K.
- Price is -17.8% vs its 50-day average ($5.00) and -34.4% vs its 200-day average ($6.27).
- 52-week range $3.93–$8.74; today's close sits at 4% of that range, 53.0% below the 52-week high.
Oct 8, 2026 — UNCY dips 2.6% to $4.07, a 52-week low
- Closed at $4.07, -2.63% vs the prior close of $4.18. Day range $4.03–$4.20, opened at $4.16.
- Volume was 1.18M shares, 1.4x its 50-day average of 826.17K.
- Price is -19.0% vs its 50-day average ($5.03) and -35.1% vs its 200-day average ($6.28).
- 52-week range $3.93–$8.74; today's close sits at 3% of that range, 53.4% below the 52-week high.
Oct 7, 2026 — UNCY dips 1.2% to $4.18, a 52-week low
- Closed at $4.18, -1.18% vs the prior close of $4.23. Day range $4.08–$4.22, opened at $4.15.
- Volume was 590.70K shares, 0.7x its 50-day average of 834.49K.
- Price is -17.1% vs its 50-day average ($5.04) and -33.5% vs its 200-day average ($6.28).
- 52-week range $3.93–$8.74; today's close sits at 5% of that range, 52.2% below the 52-week high.
Oct 6, 2026 — UNCY rises 1.0% to $4.23
- Closed at $4.23, +0.95% vs the prior close of $4.19. Day range $4.15–$4.29, opened at $4.20.
- Volume was 785.40K shares, 0.9x its 50-day average of 831.42K.
- Price is -16.3% vs its 50-day average ($5.05) and -32.7% vs its 200-day average ($6.29).
- 52-week range $3.93–$8.74; today's close sits at 6% of that range, 51.6% below the 52-week high.
Oct 5, 2026 — UNCY dips 0.7% to $4.19, a 52-week low, 3 down days in a row
- Closed at $4.19, -0.71% vs the prior close of $4.22. Day range $4.12–$4.28, opened at $4.22.
- Volume was 681.40K shares, 0.8x its 50-day average of 827.74K.
- Price is -17.4% vs its 50-day average ($5.07) and -33.4% vs its 200-day average ($6.29).
- 52-week range $3.93–$8.74; today's close sits at 5% of that range, 52.1% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — UNCY slides 7.3% to $4.22, a 52-week low on 1.9x normal volume
- Closed at $4.22, -7.25% vs the prior close of $4.55. Day range $4.09–$4.62, opened at $4.62.
- Volume was 1.51M shares, 1.9x its 50-day average of 810.53K — unusually heavy trading.
- Price is -17.2% vs its 50-day average ($5.10) and -33.1% vs its 200-day average ($6.30).
- 52-week range $3.93–$8.74; today's close sits at 6% of that range, 51.7% below the 52-week high.
UNCY latest news & SEC filings
Every SEC filing by or about UNCY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 8.01 — Reported other events the company considers important.
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$1.72M (prior year -$6.45M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.06 (prior year -$0.52) (loss narrowed vs Jun 30, 2025)
Jul 30, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 28, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 28, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 22, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Jun 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade UNCY
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 30, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.63% (largest 7.9%).
- Liquidity: about 951.40K shares (≈$3.20M) trade per day on average.
- 52-week position: $3.36 vs a range of $3.35–$8.74 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:10 on Jun 20, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 29, 2026; 8-K Sep 28, 2026; 8-K Aug 12, 2026.
- Share count: 27.86M shares outstanding (Aug 12, 2026), +57.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
UNCY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.58 | 3.58 | 3.35 | 3.36 | 1.08M |
| Oct 15, 2026 | 3.70 | 3.71 | 3.56 | 3.59 | 893.00K |
| Oct 14, 2026 | 3.73 | 3.81 | 3.59 | 3.70 | 1.21M |
| Oct 13, 2026 | 3.99 | 4.02 | 3.67 | 3.73 | 1.84M |
| Oct 12, 2026 | 4.10 | 4.11 | 3.99 | 4.05 | 912.80K |
| Oct 9, 2026 | 4.07 | 4.20 | 4.05 | 4.11 | 551.40K |
| Oct 8, 2026 | 4.16 | 4.20 | 4.03 | 4.07 | 1.18M |
| Oct 7, 2026 | 4.15 | 4.22 | 4.08 | 4.18 | 590.70K |
| Oct 6, 2026 | 4.20 | 4.29 | 4.15 | 4.23 | 785.40K |
| Oct 5, 2026 | 4.22 | 4.28 | 4.12 | 4.19 | 681.40K |
| Oct 2, 2026 | 4.62 | 4.62 | 4.09 | 4.22 | 1.51M |
| Oct 1, 2026 | 4.71 | 4.76 | 4.55 | 4.55 | 1.07M |
| Sep 30, 2026 | 4.61 | 4.81 | 4.57 | 4.70 | 862.70K |
| Sep 29, 2026 | 4.66 | 4.70 | 4.28 | 4.55 | 2.31M |
| Sep 28, 2026 | 4.66 | 4.68 | 4.53 | 4.64 | 601.50K |
| Sep 25, 2026 | 4.83 | 4.85 | 4.66 | 4.70 | 494.10K |
| Sep 24, 2026 | 4.81 | 4.86 | 4.62 | 4.81 | 660.30K |
| Sep 23, 2026 | 4.94 | 4.96 | 4.73 | 4.81 | 771.80K |
| Sep 22, 2026 | 4.80 | 4.97 | 4.76 | 4.96 | 587.70K |
| Sep 21, 2026 | 4.85 | 4.85 | 4.74 | 4.77 | 448.40K |
About Unicycive Therapeutics
Unicycive Therapeutics (UNCY) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in MOUNTAIN VIEW, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1766140.
UNCY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Shalabh K. Gupta | CEO | Jun 15, 2026 |
| Sara Kenkare-Mitra | Director | Jul 28, 2026 |
| Sandeep Laumas | Director | Jul 28, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Pramod Gupta | EVP, Pharmaceuticals and BD | Jun 15, 2026 |
| Shalabh K. Gupta | CEO | Jun 15, 2026 |
| Douglas Jermasek | EVP, Corporate Strategy | Jun 15, 2026 |
| John Townsend | CFO | Jun 15, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
UNCY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-26.55M | -1.67 | $-31.32M |
| Dec 31, 2024 | — | $-36.73M | -5.65 | $-28.57M |
| Dec 31, 2023 | $675.00K | $-30.54M | -1.28 | $-18.28M |
| Dec 31, 2022 | $951.00K | $-18.06M | -1.20 | $-15.65M |
| Dec 31, 2021 | — | $-10.02M | -0.86 | $-5.77M |
Latest balance sheet: total assets $72.03M, total liabilities $18.76M, cash $44.19M (as of Jun 30, 2026).
UNCY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $5.39 |
| May 12, 2026 | 8-K Item 2.02 (results) | $8.17 |
| Mar 30, 2026 | 8-K Item 2.02 (results) | $6.11 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $5.14 |
| Oct 28, 2025 | 8-K Item 2.02 (results) | $4.72 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $4.63 |
| Jun 30, 2025 | 8-K Item 2.02 (results) | $4.77 |
| May 14, 2025 | 8-K Item 2.02 (results) | $5.58 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $5.75 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $4.78 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on UNCY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.